| 标题 |
[高分]
专利、报告等 HERIZON-BTC-302: A phase 3 study of zanidatamab with standard-of-care (SOC) therapy vs SOC alone for first-line treatment of human epidermal growth factor receptor 2 (HER2)-positive advanced/metastatic biliary tract cancer (BTC) |
| 网址 | |
| DOI | |
| 其它 | 需要会议poster,不仅仅是abstract |
| 求助人 | |
| 下载 |
PDF的下载单位、IP信息已删除
(2025-6-4)